530 related articles for article (PubMed ID: 32521690)
1. The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
Happé C; Kurakula K; Sun XQ; da Silva Goncalves Bos D; Rol N; Guignabert C; Tu L; Schalij I; Wiesmeijer KC; Tura-Ceide O; Vonk Noordegraaf A; de Man FS; Bogaard HJ; Goumans MJ
Cells; 2020 Jun; 9(6):. PubMed ID: 32521690
[No Abstract] [Full Text] [Related]
2. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
[TBL] [Abstract][Full Text] [Related]
3. Altered TGFβ/SMAD Signaling in Human and Rat Models of Pulmonary Hypertension: An Old Target Needs Attention.
Sanada TJ; Sun XQ; Happé C; Guignabert C; Tu L; Schalij I; Bogaard HJ; Goumans MJ; Kurakula K
Cells; 2021 Jan; 10(1):. PubMed ID: 33419137
[TBL] [Abstract][Full Text] [Related]
4. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
Gomez-Puerto MC; van Zuijen I; Huang CJ; Szulcek R; Pan X; van Dinther MA; Kurakula K; Wiesmeijer CC; Goumans MJ; Bogaard HJ; Morrell NW; Rana AA; Ten Dijke P
J Pathol; 2019 Nov; 249(3):356-367. PubMed ID: 31257577
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension.
Morty RE; Nejman B; Kwapiszewska G; Hecker M; Zakrzewicz A; Kouri FM; Peters DM; Dumitrascu R; Seeger W; Knaus P; Schermuly RT; Eickelberg O
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1072-8. PubMed ID: 17347486
[TBL] [Abstract][Full Text] [Related]
6. Smad signaling in the rat model of monocrotaline pulmonary hypertension.
Ramos MF; Lamé MW; Segall HJ; Wilson DW
Toxicol Pathol; 2008 Feb; 36(2):311-20. PubMed ID: 18367643
[TBL] [Abstract][Full Text] [Related]
7. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
[TBL] [Abstract][Full Text] [Related]
8. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
Hautefort A; Mendes-Ferreira P; Sabourin J; Manaud G; Bertero T; Rucker-Martin C; Riou M; Adão R; Manoury B; Lambert M; Boet A; Lecerf F; Domergue V; Brás-Silva C; Gomez AM; Montani D; Girerd B; Humbert M; Antigny F; Perros F
Circulation; 2019 Feb; 139(7):932-948. PubMed ID: 30586714
[TBL] [Abstract][Full Text] [Related]
9. BMPR2-expressing bone marrow-derived endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo.
Harper RL; Maiolo S; Ward RJ; Seyfang J; Cockshell MP; Bonder CS; Reynolds PN
Respirology; 2019 Nov; 24(11):1095-1103. PubMed ID: 30977250
[TBL] [Abstract][Full Text] [Related]
10. Impaired Interleukin-15 Signaling via
Hilton LR; Rätsep MT; VandenBroek MM; Jafri S; Laverty KJ; Mitchell M; Theilmann AL; Smart JA; Hawke LG; Moore SD; Renaud SJ; Soares MJ; Morrell NW; Ormiston ML
Hypertension; 2022 Nov; 79(11):2493-2504. PubMed ID: 36043416
[TBL] [Abstract][Full Text] [Related]
11. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Wang Y; Zhang XH; Wang HL
Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
[TBL] [Abstract][Full Text] [Related]
12. MED1 Regulates BMP/TGF-β in Endothelium: Implication for Pulmonary Hypertension.
Wang C; Xing Y; Zhang J; He M; Dong J; Chen S; Wu H; Huang HY; Chou CH; Bai L; He F; She J; Su A; Wang Y; Thistlethwaite PA; Huang HD; Yuan JX; Yuan ZY; Shyy JY
Circ Res; 2022 Oct; 131(10):828-841. PubMed ID: 36252121
[TBL] [Abstract][Full Text] [Related]
13. The transforming growth factor-β-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease.
Upton PD; Morrell NW
Exp Physiol; 2013 Aug; 98(8):1262-6. PubMed ID: 23645549
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
McMurtry MS; Moudgil R; Hashimoto K; Bonnet S; Michelakis ED; Archer SL
Am J Physiol Lung Cell Mol Physiol; 2007 Apr; 292(4):L872-8. PubMed ID: 17142350
[TBL] [Abstract][Full Text] [Related]
15. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
[TBL] [Abstract][Full Text] [Related]
16. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension.
Hwangbo C; Lee HW; Kang H; Ju H; Wiley DS; Papangeli I; Han J; Kim JD; Dunworth WP; Hu X; Lee S; El-Hely O; Sofer A; Pak B; Peterson L; Comhair S; Hwang EM; Park JY; Thomas JL; Bautch VL; Erzurum SC; Chun HJ; Jin SW
Circulation; 2017 Jun; 135(23):2288-2298. PubMed ID: 28356442
[TBL] [Abstract][Full Text] [Related]
18. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.
Song Y; Coleman L; Shi J; Beppu H; Sato K; Walsh K; Loscalzo J; Zhang YY
Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H677-90. PubMed ID: 18552156
[TBL] [Abstract][Full Text] [Related]
19. BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling.
Harper RL; Reynolds AM; Bonder CS; Reynolds PN
Respirology; 2016 May; 21(4):727-33. PubMed ID: 26809239
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension.
Kabwe JC; Sawada H; Mitani Y; Oshita H; Tsuboya N; Zhang E; Maruyama J; Miyasaka Y; Ko H; Oya K; Ito H; Yodoya N; Otsuki S; Ohashi H; Okamoto R; Dohi K; Nishimura Y; Mashimo T; Hirayama M; Maruyama K
Respir Res; 2022 Apr; 23(1):87. PubMed ID: 35395852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
